Celia Martín-Cuevas

Celia Martín-Cuevas

Auto-generated profile, based on publicly available information

Celia Martín-Cuevas

Translational Psychiatry, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Sevilla, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2025 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
AVAna Isabel Valderrama-Mantilla
Ana Isabel Valderrama-Mantilla
CMCelia Martín-Cuevas
Celia Martín-Cuevas
AGAna Gómez-Garrido
Ana Gómez-Garrido
CMCristina Morente-Montilla
Cristina Morente-Montilla
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
Susana García-CerroSusana García-Cerro
Susana García-Cerro
The Reelin signaling pathway, particularly the RELN-APOER2-DAB1 complex, has emerged as a key contributor to the neuropathology of Alzheimer's disease (AD) and Schizophrenia (SZ). Despite being distinct clinical conditions, these disorders exhibit similar patterns of cognitive decline, including early disruptions in synaptic function and memory impairments. Notably, individuals with SZ have a 2-4 fold increased risk of developing AD or other dementias, highlighting potential shared molecular mechanisms, and positioning Reelin as a pivotal link between them. This systematic review explores the role of Reelin and its signaling components across these disorders. In AD, Reelin disruption correlates with hallmark features such as Tau hyperphosphorylation, amyloid-beta accumulation, and cognitive deficits. In SZ, alterations in Reelin signaling, including epigenetic modifications affecting RELN expression, are linked to disruptions in neuronal development and synaptic plasticity, particularly in the parietal and prefrontal cortices. Additionally, genomic studies reveal specific RELN variants and allelic imbalances that may influence disease severity and treatment response in SZ, suggesting RELN's role as a potential biomarker for therapeutic outcomes. Region-specific Reelin alterations in both AD and SZ suggest differing impacts yet underscore a potential common molecular origin. Our findings highlight the Reelin pathway as a molecular convergence point, warranting further investigation as a therapeutic and diagnostic target for AD, SZ, and potentially other neuropsychiatric disorders. The interplay between genetic and epigenetic regulation of RELN may provide novel insights into neurodegeneration, with implications for personalized intervention strategies in AD and SZ.

30 September 2023 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
CMCelia Martín-Cuevas
Celia Martín-Cuevas
VRVictor Ramos
Victor Ramos
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
ASAna C. Sánchez-Hidalgo
Ana C. Sánchez-Hidalgo

24 October 2025 in Science Advances
Verified
Journal Article
Open access
TDTeresa C Delgado
Teresa C Delgado
CMCelia Martín-Cuevas
Celia Martín-Cuevas
AHAna C. Sánchez Hidalgo
Ana C. Sánchez Hidalgo
AGAntonio Gil-Gomez
Antonio Gil-Gomez
CRClaudia María Rejano-Gordillo
Claudia María Rejano-Gordillo
Maria Luz Martinez-ChantarMaria Luz Martinez-Chantar
Maria Luz Martinez-Chantar
Metabolic dysfunction–associated steatotic liver disease (MASLD), a liver-centric condition, is associated with cognitive impairment and sensorimotor alterations. However, it remains unclear whether MASLD is sufficient to drive central nervous system deficits. Here, using diet-induced mouse models, we showed that MASLD was associated with alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished dentate gyrus neurogenesis and neuronal differentiation. Then, we selectively modulated liver metabolism through N -acetylgalactosamine small interfering RNA (siRNA) therapy against Cyclin M4 ( CNNM4 ), a magnesium transporter dysregulated in MASLD. Liver-specific intervention with siRNA- Cnnm4 reversed impaired social memory and sensorimotor processing in association with recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis for MASLD-associated neurological complications.

30 March 2026 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
IFInés Lucía Fernández-Pech
Inés Lucía Fernández-Pech
MFMaría Fernández-Guillén
María Fernández-Guillén
CMCristina Morente-Montilla
Cristina Morente-Montilla
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
CMCelia Martín-Cuevas
Celia Martín-Cuevas
Psychiatric disorders are characterized by marked clinical heterogeneity, overlapping symptom dimensions, and the persistent lack of objective biomarkers. Liquid biopsy has emerged as a promising, non-invasive strategy to identify peripheral molecular signatures that may inform diagnosis and treatment monitoring. Given the central involvement of mitochondrial dysfunction in psychiatric pathophysiology, circulating cell-free mitochondrial DNA (ccf-mtDNA) has attracted increasing interest as a candidate biomarker. Following PRISMA 2020 guidelines, this systematic review synthesized evidence on ccf-mtDNA alterations in bipolar disorder (BD), depressive disorders (DD), and schizophrenia (SCZ). Findings in BD were heterogeneous: several studies reported elevated ccf-mtDNA, particularly in unmedicated individuals and those with cognitive deficits, whereas others observed no differences or even decreased levels compared with healthy controls (HC). In DD, evidence more consistently indicated increased ccf-mtDNA, especially in unmedicated or late-life depression, where higher levels correlated with symptom severity, frailty, and inflammatory indices. These data support ccf-mtDNA as a peripheral marker of mitochondrial and inflammatory dysregulation in DD. Conversely, most studies in SCZ reported no significant differences relative to HC; however, elevated ccf-mtDNA levels observed in cognitively impaired subgroups and in patients exhibiting alterations in brain bioenergetics point to underlying clinical and biological heterogeneity. Collectively, current evidence implicates ccf-mtDNA as a putative biomarker of mitochondrial dysfunction in psychiatry, with greater translational potential in DD and BD. Nonetheless, methodological heterogeneity, small sample sizes, and cross-sectional designs underscore the need for standardized, longitudinal investigations to establish its diagnostic and prognostic validity.

4 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
CMCelia Martín-Cuevas
Celia Martín-Cuevas
VRVictor Ramos
Victor Ramos
MMMaría Molina-Fossati
María Molina-Fossati
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro
ASAna Sánchez-Hidalgo
Ana Sánchez-Hidalgo

5 November 2023 in IBRO Neuroscience Reports
Verified
Journal Article
Open access
ASAna Sánchez-Hidalgo
Ana Sánchez-Hidalgo
CMCelia Martín-Cuevas
Celia Martín-Cuevas
AFAlvaro Flores-Martínez
Alvaro Flores-Martínez
VRVictor Ramos
Victor Ramos
ICIsabel Cortines-Serrano
Isabel Cortines-Serrano
BCBenedicto Crespo-Facorro
Benedicto Crespo-Facorro